Differential effects of β-blockers, Angiotensin II receptor blockers, and a novel AT2R agonist NP-6A4 on stress response of nutrient-starved cardiovascular cells

PLoS ONE

Volumn 10, Issue 12, 2015, Pages

  Mahmood, Abuzar ^a,b   Pulakat, Lakshmi ^a,b  

^a UNIVERSITY OF MISSOURI   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN 2 RECEPTOR; ATENOLOL; CARDIOVASCULAR AGENT; CARVEDILOL; CGP 42112 A; LOSARTAN; METOPROLOL; NEBIVOLOL; NP 6 A 4; PHOSPHOLIPASE C GAMMA; PROTEIN MCL 1; UNCLASSIFIED DRUG; ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT;

ANIMAL CELL; ARTICLE; CELL PROLIFERATION ASSAY; CELL SIZE; CELL SURVIVAL; CELL VIABILITY; CONTROLLED STUDY; DRUG RESPONSE; ENZYME INHIBITION; HEART MUSCLE CELL; HUMAN; HUMAN CELL; IMMUNOFLUORESCENCE; MOUSE; NONHUMAN; PROTEIN EXPRESSION; REGULATORY MECHANISM; STARVATION; STRESS; VASCULAR SMOOTH MUSCLE CELL; AGONISTS; ANIMAL; CELL LINE; CYTOLOGY; IMMUNOLOGY; METABOLISM; PHYSIOLOGICAL STRESS; SMOOTH MUSCLE CELL; VASCULAR SMOOTH MUSCLE;

ADRENERGIC BETA-ANTAGONISTS; ANGIOTENSIN RECEPTOR ANTAGONISTS; ANIMALS; CELL LINE; HUMANS; MICE; MUSCLE, SMOOTH, VASCULAR; MYOCYTES, SMOOTH MUSCLE; RECEPTOR, ANGIOTENSIN, TYPE 2; STRESS, PHYSIOLOGICAL;

EID: 84957309995     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0144824     Document Type: Article

References (51)

1. World health Organization (2014). The top 10 causes of death. http://www.who.int/mediacentre/ factsheets/fs310/en/
2. Center for Disease Control and Prevention Fact Sheets (Feb 6th 2015). Leading Causes of Death. http://www.cdc.gov/nchs/fastats/leading-causes-of-Death.htm
3. Ong SB, Samangouei P, Kalkhoran SB, Hausenloy DJ. The mitochondrial permeability transition pore and its role in myocardial ischemia reperfusion injury. J Mol Cell Cardiol. 2015 Jan; 78:23-34 doi: 10.1016/j.yjmcc.2014.11.005 PMID: 25446182
4. Badalzadeh R, Mokhtari B, Yavari R. Contribution of apoptosis in myocardial reperfusion injury and loss of cardioprotection in diabetes mellitus. J Physiol Sci. 2015 May; 65(3):201-15 doi: 10.1007/ s12576-015-0365-8 PMID: 25726180
5. Gatica D, Chiong M, Lavandero S, Klionsky DJ. Molecular mechanisms of autophagy in the cardiovascular system. irc Res. 2015 Jan 30; 116(3):456-67
6. Hashem SI, Perry CN, Bauer M, Han S, Clegg SD, Ouyang K et al. Oxidative Stress Mediates Cardiomyocyte Apoptosis in a Human Model of Danon Disease and Heart Failure. Stem Cells. 2015 Jul; 33 (7):2343-50. doi: 10.1002/stem.2015 PMID: 25826782
7. Su Q, Li L, Liu YC, Zhou Y, Lu YG, Wen WM. Effect of metoprolol on myocardial apoptosis and caspase-9 activation after coronary microembolization in rats. Exp Clin Cardiol. 2013 Spring; 18(2):161-5. PMID: 23940444
8. Wang Y, Wang Y, Yang D, Yu X, Li H, Lv X et al. β1-Adrenoceptor stimulation promotes LPS-induced cardiomyocyte apoptosis through activating PKA and enhancing CaMKII and I?Ba phosphorylation. Crit Care. 2015 Mar 9; 19(1):76.
9. Keating GM, Jarvis B. Carvedilol: a review of its use in chronic heart failure. Drugs. 2003; 63(16):1697-741. PMID: 12904089
10. Zhang Z, Ding L, Jin Z, Gao G, Li H, Zhang L et al. Nebivolol protects against myocardial infarction injury via stimulation of beta 3-Adrenergic receptors and nitric oxide signaling. PLoS One. 2014 May 21; 9(5):e98179 doi: 10.1371/journal.pone.0098179 PMID: 24849208
11. Sato M, Engelman RM, Otani H, Maulik N, Rousou JA, Flack JE 3rd, et al. Myocardial protection by preconditioning of heart with losartan, an angiotensin II type 1-receptor blocker: implication of bradykinindependent and bradykinin-independent mechanisms. Circulation. 2000 Nov 7; 102(19 Suppl 3):III346-51. PMID: 11082412
12. Blessberger H, Kammler J, Domanovits H, Schlager O, Wildner B, Azar D, et al. Perioperative betablockers for preventing surgery-related mortality and morbidity. Cochrane Database Syst Rev. 2014 Sep 18; 9:CD004476. doi: 10.1002/14651858.CD004476.pub2 PMID: 25233038
13. Amann U, Kirchberger I, Heier M, Golüke H, von ScheidtW, Kuch B, et al. Long-Term survival in patients with different combinations of evidence-based medications after incident acute myocardial infarction: results from the MONICA/KORA Myocardial Infarction Registry. Clin Res Cardiol. 2014 Aug; 103 (8):655-64. doi: 10.1007/s00392-014-0688-0 PMID: 24604524
14. Thompson PL. Should β-blockers still be routine after myocardial infarction? Curr Opin Cardiol. 2013 Jul; 28(4):399-404. doi: 10.1097/HCO.0b013e328361e97a PMID: 23703252
15. Grimm C, Köberlein J, Wiosna W, Kresimon J, Kiencke P, Rychlik R. New-onset diabetes and antihypertensive treatment. GMS Health Technol Assess. 2010 Mar 16; 6:Doc03. doi: 10.3205/hta000081 PMID: 21289876
16. Vardeny O, Uno H, Braunwald E, Rouleau JL, Gersh B, Maggioni AP et al. Prevention of Events with an ACE Inhibitor (PEACE) Investigators. Opposing effects of β blockers and angiotensin-converting enzyme inhibitors on development of new-onset diabetes mellitus in patients with stable coronary artery disease. Am J Cardiol. 2011 Jun 15; 107(12):1705-9 doi: 10.1016/j.amjcard.2011.01.064 PMID: 21507365
17. Gupta S, Wright HM. Nebivolol: a highly selective beta1-Adrenergic receptor blocker that causes vasodilation by increasing nitric oxide. Cardiovasc Ther. 2008 Fall; 26(3):189-202 doi: 10.1111/j.1755-5922.2008.00054.x PMID: 18786089
18. Erickson CE, Gul R, Blessing CP, Nguyen J, Liu T, Pulakat L et al. The β-blocker Nebivolol Is a GRK/β-Arrestin biased agonist. PLoS One. 2013 Aug 20; 8(8):e71980. doi: 10.1371/journal.pone.0071980 PMID: 23977191
19. Gul R, Demarco VG, Sowers JR, Whaley-Connell A, Pulakat L. Regulation of Overnutrition-Induced Cardiac Inflammatory Mechanisms. Cardiorenal Med. 2012 Aug; 2(3):225-233. PMID: 22969779
20. Ladage D, Reidenbach C, Rieckeheer E, Graf C, Schwinger RH, Brixius K. Nebivolol lowers blood pressure and increases weight loss in patients with hypertension and diabetes in regard to age. J Cardiovasc Pharmacol. 2010 Sep; 56(3):275-81. PMID: 20571428 doi: 10.1097/FJC.0b013e3181eb4ff2
21. Gul R, Mahmood A, Luck C, Lum-Naihe K, Alfadda AA, Speth RC et al. Regulation of cardiac miR-208a, an inducer of obesity, by Rapamycin and Nebivolol. Obesity (Silver Spring). 2015 Nov; 23 (11):2251-9
22. Gul R, Ramdas M, Mandavia C, Sowers JR and Pulakat L. RAS-mediated adaptive mechanisms in cardiovascular tissues: Confounding factors of RAS blockade therapy and alternative approaches. 2012. Cardiorenal Med, ( 4):268-280.
23. Akazawa H, Yabumoto C, Yano M, Kudo-Sakamoto Y, Komuro I. ARB and cardioprotection. Cardiovasc Drugs Ther. 2013 Apr; 27(2):155-60 doi: 10.1007/s10557-012-6392-2 PMID: 22538956
24. Kajstura J, Cigola E, Malhotra A, Li P, Cheng W, Meggs LG et al. Angiotensin II induces apoptosis of adult ventricular myocytes in vitro. J Mol Cell Cardiol 1997, 29:859-870. PMID: 9152847
25. Yang C, Liu Z, Liu K, Yang P. Mechanisms of Ghrelin anti-heart failure: inhibition of Ang II-induced cardiomyocyte apoptosis by down-regulating AT1R expression. PLoS One. 2014 Jan 21; 9(1):e85785 doi: 10.1371/journal.pone.0085785 PMID: 24465706
26. Strauss MH, Hall AS. Angiotensin receptor blockers may increase risk of myocardial infarction: unraveling the ARB-MI paradox. Circulation. 2006 Aug 22; 114(8):838-54. PMID: 16923768
27. Altarche-XifróW, Curato C, Kaschina E, Grzesiak A, Slavic S, Dong J, et al. Cardiac c-kit+AT2+ cell population is increased in response to ischemic injury and supports cardiomyocyte performance. Stem Cells. 2009 Oct; 27(10):2488-97 doi: 10.1002/stem.171 PMID: 19591228
28. Ludwig M, Steinhoff G, Li J. The regenerative potential of angiotensin AT2 receptor in cardiac repair. Can J Physiol Pharmacol. 2012 Mar; 90(3):287-93. doi: 10.1139/y11-108 PMID: 22364522
29. Kumar V, Knowle D, Gavini N, Pulakat L. Identification of the region of AT2 receptor needed for inhibition of the AT1 receptor-mediated inositol 1,4,5-Triphosphate generation. FEBS Lett. 2002 Dec 18; 532 (3):379-86. PMID: 12482596
30. Kajstura J, Cigola E, Malhotra A, Li P, Cheng W, Meggs LG, et al. Angiotensin II induces apoptosis of adult ventricular myocytes in vitro. J Mol Cell Cardiol. 1997 Mar; 29(3):859-70 PMID: 9152847
31. Sugino H, Ozono R, Kurisu S, Matsuura H, Ishida M, Oshima T et al. Apoptosis is not increased in myocardium overexpressing type 2 angiotensin II receptor in transgenic mice. Hypertension. 2001 Jun; 37 (6):1394-8. PMID: 11408383
32. Troncoso R, Vicencio JM, Parra V, Nemchenko A, Kawashima Y, Del Campo A et al. Energy-preserving effects of IGF-1 antagonize starvation-induced cardiac autophagy. Cardiovasc Res. 2012 Feb 1; 93 (2):320-9 doi: 10.1093/cvr/cvr321 PMID: 22135164
33. Ma X, Liu H, Foyil SR, Godar RJ, Weinheimer CJ, Hill JA et al. Impaired autophagosome clearance contributes to cardiomyocyte death in ischemia/reperfusion injury. Circulation. 2012 Jun 26; 125 (25):3170-81 doi: 10.1161/CIRCULATIONAHA.111.041814 PMID: 22592897
34. Ke N, Nguyen K, Irelan J, Abassi YA. Multidimensional GPCR profiling and screening using impedance-based label-free and real-Time assay. Methods Mol Biol. 2015; 1272:215-26. doi: 10.1007/978-1-4939-2336-6-15 PMID: 25563187
35. Ramis G, Martínez-Alarcón L, Quereda JJ, Mendonça L, Majado MJ, Gomez-Coelho K et al. Optimization of cytotoxicity assay by real-Time, impedance-based cell analysis. Biomed Microdevices. 2013 Dec; 15(6):985-95 doi: 10.1007/s10544-013-9790-8 PMID: 23887614
36. Thomas RL, Roberts DJ, Kubli DA, Lee Y, Quinsay MN, Owens JB et al. Loss of MCL-1 leads to impaired autophagy and rapid development of heart failure. Genes Dev. 2013 Jun 15; 27(12):1365-77 doi: 10.1101/gad.215871.113 PMID: 23788623
37. Wang X, Bathina M, Lynch J, Koss B, Calabrese C, Frase S, Schuetz JD et al. Deletion of MCL-1 causes lethal cardiac failure and mitochondrial dysfunction. Genes Dev. 2013 Jun 15; 27(12):1351-64 doi: 10.1101/gad.215855.113 PMID: 23788622
38. Arnold N, Koppula PR, Gul R, Luck C, Pulakat L. Regulation of cardiac expression of the diabetic marker microRNA miR-29. PLoS One. 2014 Jul 25; 9(7):e103284 doi: 10.1371/journal.pone.0103284 PMID: 25062042
39. Ibe JC, Zhou Q, Chen T, Tang H, Yuan JX, Raj JU et al. Adenosine monophosphate-Activated protein kinase is required for pulmonary artery smooth muscle cell survival and the development of hypoxic pulmonary hypertension. Am J Respir Cell Mol Biol. 2013 Oct; 49(4):609-18 doi: 10.1165/rcmb.2012-0446OC PMID: 23668615
40. Rinkenberger JL, Horning S, Klocke B, Roth K, Korsmeyer SJ. Mcl-1 deficiency results in peri-implantation embryonic lethality. Genes Dev. 2000 Jan 1; 14(1):23-7 PMID: 10640272
41. White SM, Constantin PE, Claycomb WC. Cardiac physiology at the cellular level: use of cultured HL-1 cardiomyocytes for studies of cardiac muscle cell structure and function. Am J Physiol Heart Circ Physiol 2004; 286: H823-H829. PMID: 14766671
42. Parenti A, Filippi S, Amerini S, Granger HJ, Fazzini A, Ledda F. Inositol phosphate metabolism and nitric-oxide synthase activity in endothelial cells are involved in the vasorelaxant activity of nebivolol. J Pharmacol Exp Ther. 2000 Feb; 292(2):698-703. PMID: 10640308
43. Mangat R, Singal T, Dhalla NS, Tappia PS. Inhibition of phospholipase C-gamma 1 augments the decrease in cardiomyocyte viability by H2O2. Am J Physiol Heart Circ Physiol. 2006 Aug; 291(2): H854-60. PMID: 16501016
44. Xiao L, Haack KK, Zucker IH. Angiotensin II regulates ACE and ACE2 in neurons through p38 mitogenactivated protein kinase and extracellular signal-regulated kinase 1/2 signaling. Am J Physiol Cell Physiol. 2013 Jun 1; 304(11):C1073-9 doi: 10.1152/ajpcell.00364.2012 PMID: 23535237
45. Falcón BL, Veerasingham SJ, Sumners C, Raizada MK. Angiotensin II type 2 receptor-mediated gene expression profiling in human coronary artery endothelial cells. Hypertension. 2005 Apr; 45(4):692-7 PMID: 15710780
46. Brunt KR, Tsuji MR, Lai JH, Kinobe RT, Durante W, ClaycombWC et al. Heme Oxygenase-1 Inhibits Pro-Oxidant Induced Hypertrophy in HL-1 Cardiomyocytes. Experimental biology and medicine (Maywood, NJ). 2009; 234(5):582-594.
47. Ke N, Wang X, Xu X, Abassi YA. The xCELLigence system for real-Time and label-free monitoring of cell viability. Methods Mol Biol. 2011; 740:33-43 doi: 10.1007/978-1-61779-108-6-6 PMID: 21468966
48. Knowle D, Kurfis J, Gavini N, Pulakat L. Role of Asp297 of the AT2 receptor in high-Affinity binding to different peptide ligands. Peptides. 2001 Dec; 22(12):2145-9 PMID: 11786202
49. Pulakat L, Gray A, Johnson J, Knowle D, Burns V, Gavini N. Role of C-Terminal cytoplasmic domain of the AT2 receptor in ligand binding and signaling. FEBS Lett. 2002 Jul 31; 524(1-3):73-8. PMID: 12135744
50. Solaini G, Baracca A, Lenaz G, Sgarbi G. Hypoxia and mitochondrial oxidative metabolism. Biochim Biophys Acta. 2010 Jun-Jul; 1797(6-7):1171-7 doi: 10.1016/j.bbabio.2010.02.011 PMID: 20153717
51. Perciavalle RM, Stewart DP, Koss B, Lynch J, Milasta S, Bathina M et al. Anti-Apoptotic MCL-1 localizes to the mitochondrial matrix and couples mitochondrial fusion to respiration. Nat Cell Biol. 2012 Apr 29; 14(6):575-83. doi: 10.1038/ncb2488 PMID: 22544066